Whitehawk Therapeutics (NASDAQ:WHWK) Posts Quarterly Earnings Results, Beats Expectations By $0.21 EPS

Whitehawk Therapeutics (NASDAQ:WHWK) issued its quarterly earnings results on Thursday. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.21, FiscalAI reports.

Whitehawk Therapeutics Trading Down 2.7%

WHWK stock opened at $3.90 on Friday. Whitehawk Therapeutics has a 52 week low of $1.39 and a 52 week high of $4.48. The company has a market capitalization of $183.81 million, a price-to-earnings ratio of 27.86 and a beta of 0.51. The firm’s 50-day moving average is $2.99 and its two-hundred day moving average is $2.46.

Analyst Ratings Changes

A number of brokerages have weighed in on WHWK. JonesTrading started coverage on Whitehawk Therapeutics in a report on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Monday, December 29th. Finally, Oppenheimer initiated coverage on shares of Whitehawk Therapeutics in a report on Thursday, February 5th. They issued an “outperform” rating and a $6.00 price target on the stock. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $6.50.

Institutional Investors Weigh In On Whitehawk Therapeutics

Several institutional investors have recently bought and sold shares of WHWK. Orbimed Advisors LLC bought a new position in Whitehawk Therapeutics in the 3rd quarter worth about $7,915,000. Suvretta Capital Management LLC bought a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth $7,030,000. Acuta Capital Partners LLC acquired a new position in shares of Whitehawk Therapeutics in the third quarter valued at $6,480,000. Avoro Capital Advisors LLC acquired a new stake in Whitehawk Therapeutics during the third quarter worth approximately $5,414,000. Finally, KVP Capital Advisors LP purchased a new stake in Whitehawk Therapeutics in the 4th quarter worth about $5,242,000. Institutional investors own 52.08% of the company’s stock.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.